Cholinesterases (Cholinesterase)

04/01/1994 - "Taken together with our earlier work, which has failed to demonstrate mnemonic deficits following lesions to the magnocellular neurons of the nucleus basalis of Meynert, these results suggest that the most consistent deficit produced following lesions of the BF-cortical cholinergic system is attentional dysfunction Analogous deficits in visual attention are also seen in patients with Alzheimer's disease, which can also be improved by anti-cholinesterase treatment."
03/01/2004 - "Cholinesterase (ChE) inhibitors are primarily used in the treatment of mild to moderate Alzheimer's disease (AD), but may also be effective in more severe disease. "
04/01/1997 - "The association of anti-inflammatory and cholinesterase inhibiting activities within the same compound may prove useful for the treatment of Alzheimer's disease."
07/01/2004 - "The authors evaluated the efficacy of a new cognitive rehabilitation program on memory and functional performance of mildly impaired Alzheimer disease (AD) patients receiving a cholinesterase inhibitor. "
07/01/2009 - "Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study."

01/01/2015 - "Recently, acetyl cholinesterase (AchE) inhibitory activity has been found in Lyc alkaloid extract, which could be beneficial in dementia disorder. "
05/01/2007 - "The present study indicate that cholinesterase inhibitor anti-dementia drugs are effective against LPS induced neuroinflammation that may be linked to enhanced cholinergic activity."
09/01/2015 - "Further, once conversion to dementia has occurred, a cholinesterase inhibitor would be started in most (if not all) clinical settings, a reality not well reflected in most study designs. "
01/01/2015 - "This population-based study determined the association of people with dementia exposed to cholinesterase inhibitor medication and pacemaker insertion. "
01/01/2015 - "The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada."

12/01/1991 - "After the cholinesterase inhibited symptoms had vanished or had improved and after the other factors had been eliminated the delayed dysneurias occur after poisoning 5.42 days. "
01/01/2015 - "The purpose of this study is to investigate the prognostic factors affecting survival in patients with cholinesterase inhibitor (CI) poisoning. "
01/01/2015 - "Fourteen patients (8 males, age 18-50 years) with acute OPC poisoning were included in the study based on the history and clinical features, documented decreased in plasma cholinesterase activity or presence of the OPC in gastric lavage/blood samples. "
11/01/2013 - "The aim of this study was to investigate the presence of myocardial damage in patients with cholinesterase poisoning.It"
07/01/2011 - "This study was conducted to see if CPK may be used as an alternative of cholinesterase levels in blood to assess the severity of OP poisoning. "

10/01/2011 - "There is evidence from a modest number of well-conducted randomized controlled trials (RCTs) that various nonpharmacological approaches, including cognitive training, cognitive rehabilitation, and cognitive stimulation therapy (CST), confer modest but significant benefits in the treatment of cognitive symptoms in people with AD, and that there may be additive benefits in combination with cholinesterase inhibitor therapy. "
03/04/2003 - "Currently available cholinesterase inhibition therapy targets the cognitive symptoms. "
01/01/1976 - "Clinical reports and laboratory investigations have generally supported the assumption that neurobehavioral manifestations of organophosphate toxicity are attributable to accumulation of acetylcholine at central and peripheral synapses as a result of cholinesterase inhibition. "
11/01/1999 - "Metrifonate is an organophosphate cholinesterase inhibitor effective in the treatment of the cognitive symptoms of Alzheimer's disease and currently under review by the U.S. "
01/01/1996 - "The present study examines the safety and efficacy of the centrally acting cholinesterase inhibitor, velnacrine, in treating the cognitive symptoms of Alzheimer's disease. "

06/01/1990 - "A model for a 'standardized' plasma cholinesterase in which the combined effects of the four significant variables, ChE-1 phenotype, sex, body weight, and height are eliminated, is proposed for comparisons of plasma cholinesterase activities in unmatched population groups, e.g. "
06/01/1990 - "Multiple regression analysis and analysis of variance showed statistically significant effects on the individual plasma cholinesterase activity by body weight, height, sex, and ChE-1 phenotype (but not by age or electrophoretic phenotype). "
01/01/2000 - "Doses for the 2-year study were based on findings in a 13-week feeding study in which lower body weights, urinary perineal staining, adrenal cortical vacuolization, and inhibition (slightly more than 60%) of brain cholinesterase (ChE) occurred at 15 mg/kg/day. "
01/01/1998 - "Body weights and plasma cholinesterase activities were measured after a 21-day study period. "
06/01/1989 - "During and after the animal feeding study, changes in body weight gain, organ weight, cholinesterase activity, serum enzyme activity, and hematology were investigated. "